Evidence map›Paper›PMID 35995596›Full record

ArticleJournal of computer assisted tomography

Interstitial Lung Abnormalities in Patients With Locally Advanced Esophageal Cancer: Prevalence, Risk Factors, and Clinical Implications.

Shu-Chi Tseng, Takuya Hino, Hiroto Hatabu, Hyesun Park, Nina N Sanford, Gigin Lin, Mizuki Nishino, Harvey Mamon

Open access · greenAbstract read
In one paragraph

Article in Journal of computer assisted tomography. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Shu-Chi Tseng
Takuya HinoFrom the Department of Radiology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, Boston, MA.
Hiroto HatabuFrom the Department of Radiology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, Boston, MA.
Hyesun ParkFrom the Department of Radiology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, Boston, MA.
Nina N SanfordDepartment of Radiation Oncology, University of Texas Southwestern, Dallas, TX.
Gigin LinDepartment of Medical Imaging and Intervention, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan, Taiwan.
Mizuki NishinoFrom the Department of Radiology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, Boston, MA.
Harvey MamonDepartment of Radiation Oncology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, Boston MA.
Chang Gung University · TWDana-Farber Brigham Cancer Center · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · USThe University of Texas Southwestern Medical Center · US

Funding

The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Interstitial Lung Abnormalities: Defining the Phenotype, Causes, and Consequences.R01HL111024 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNNINGHAKE, GARY MATTHEW · 2013 to 2022
$6.4M
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatmentR01CA203636 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NISHINO, MIZUKI · 2017 to 2021
$2.9M
Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancerR01CA240592 · NCI · DANA-FARBER CANCER INST · PI PAWELETZ, CLOUD PETER · 2020 to 2024
$2.2M
NCI NIH HHS R01 CA203636NCI NIH HHS R01 CA240592NCI NIH HHS U01 CA209414NHLBI NIH HHS R01 HL111024
6 · The paper itself

Abstract

purposeInterstitial lung abnormalities (ILAs) represent nondependent abnormalities on chest computed tomography (CT) indicating lung parenchymal damages due to inflammation and fibrosis. Interstitial lung abnormalities have been studied as a predictor of clinical outcome in lung cancer, but not in other thoracic malignancies. The present study investigated the prevalence of ILA in patients with esophageal cancer and identified risk factors and clinical implications of ILA in these patients.

methodsThe study included 208 patients with locally advanced esophageal cancer (median age, 65.6 years; 166 males, 42 females). Interstitial lung abnormality was scored on baseline CT scans before treatment using a 3-point scale (0 = no evidence of ILA, 1 = equivocal for ILA, 2 = ILA). Clinical characteristics and overall survival were compared in patients with ILA (score 2) and others.

resultsAn ILA was present in 14 of 208 patients (7%) with esophageal cancer on pretreatment chest CT. Patients with ILA were significantly older (median age, 69 vs 65, respectively; P = 0.011), had a higher number of pack-years of smoking ( P = 0.02), and more commonly had T4 stage disease ( P = 0.026) than patients with ILA score of 1 or 0. Interstitial lung abnormality on baseline scan was associated with a lack of surgical resection after chemoradiotherapy (7/14, 50% vs 39/194, 20% respectively; P = 0.016). Interstitial lung abnormality was not associated with overall survival (log-rank P = 0.75, Cox P = 0.613).

conclusionsAn ILA was present in 7% of esophageal cancer patients, which is similar to the prevalence in general population and in smokers. Interstitial lung abnormality was strongly associated with a lack of surgical resection after chemoradiotherapy, indicating an implication of ILA in treatment selection in these patients, which can be further studied in larger cohorts.

Indexed as

Esophageal NeoplasmsNeoplasms, Second PrimaryAgedFemaleHumansLungMalePrevalenceRisk Factors

Identifiers

PMID35995596
PMCPMC9675694
OpenAlexW4292686433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.